VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$6.08Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $334,091,136.00
EPSttm : -3.36
Verastem, Inc.
$6.08
1.46%$0.09Float Short %
37.03
Margin Of Safety %
Put/Call OI Ratio
0.4
EPS Next Q Diff
0.2
EPS Last/This Y
1.06
EPS This/Next Y
-0.17
Price
6.08
Target Price
15.25
Analyst Recom
1
Performance Q
-18.17
Relative Volume
0.84
Beta
0.83
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | VSTM | 4.8 | 0.21 | 0.03 | 8588 |
| 2025-07-07 | VSTM | 4.7 | 0.21 | 0.11 | 8617 |
| 2025-07-08 | VSTM | 4.71 | 0.21 | 0.06 | 8660 |
| 2025-07-09 | VSTM | 4.79 | 0.21 | 0.77 | 8701 |
| 2025-07-10 | VSTM | 4.74 | 0.22 | 0.00 | 8743 |
| 2025-07-11 | VSTM | 4.68 | 0.22 | 0.01 | 8745 |
| 2025-07-14 | VSTM | 4.95 | 0.21 | 0.16 | 8816 |
| 2025-07-15 | VSTM | 4.89 | 0.21 | 1.46 | 8872 |
| 2025-07-16 | VSTM | 5.24 | 0.29 | 0.00 | 9547 |
| 2025-07-17 | VSTM | 5.11 | 0.29 | 0.44 | 9535 |
| 2025-07-18 | VSTM | 5.16 | 0.28 | 0.52 | 9540 |
| 2025-07-21 | VSTM | 5.09 | 0.26 | 0.08 | 6393 |
| 2025-07-22 | VSTM | 5.27 | 0.24 | 1.11 | 6686 |
| 2025-07-23 | VSTM | 5.34 | 0.26 | 0.05 | 6955 |
| 2025-07-24 | VSTM | 5.3 | 0.26 | 1.19 | 6974 |
| 2025-07-25 | VSTM | 6.14 | 0.28 | 0.92 | 7085 |
| 2025-07-28 | VSTM | 6.03 | 0.37 | 0.03 | 7813 |
| 2025-07-29 | VSTM | 6.3 | 0.37 | 0.00 | 7903 |
| 2025-07-30 | VSTM | 6.24 | 0.36 | 0.51 | 7965 |
| 2025-07-31 | VSTM | 6.19 | 0.40 | 0.00 | 8742 |
| 2025-08-01 | VSTM | 6.09 | 0.40 | 0.18 | 8777 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | VSTM | 4.80 | -22.1 | - | -2.60 |
| 2025-07-07 | VSTM | 4.69 | -22.1 | - | -2.60 |
| 2025-07-08 | VSTM | 4.71 | -22.1 | - | -2.60 |
| 2025-07-09 | VSTM | 4.81 | -22.1 | - | -2.60 |
| 2025-07-10 | VSTM | 4.74 | -22.1 | - | -2.60 |
| 2025-07-11 | VSTM | 4.68 | -22.1 | - | -2.60 |
| 2025-07-14 | VSTM | 4.96 | -22.1 | - | -2.60 |
| 2025-07-15 | VSTM | 4.89 | -22.1 | - | -2.60 |
| 2025-07-16 | VSTM | 5.24 | -22.1 | - | -2.60 |
| 2025-07-17 | VSTM | 5.11 | -22.1 | - | -2.60 |
| 2025-07-18 | VSTM | 5.16 | -22.1 | - | -2.60 |
| 2025-07-21 | VSTM | 5.09 | -22.1 | - | -2.60 |
| 2025-07-22 | VSTM | 5.27 | -22.1 | - | -2.60 |
| 2025-07-23 | VSTM | 5.35 | -22.1 | - | -2.60 |
| 2025-07-24 | VSTM | 5.29 | -22.1 | - | -2.60 |
| 2025-07-25 | VSTM | 6.14 | -22.1 | - | -2.60 |
| 2025-07-28 | VSTM | 6.01 | -22.1 | - | -2.60 |
| 2025-07-29 | VSTM | 6.29 | -22.1 | - | -2.60 |
| 2025-07-30 | VSTM | 6.23 | -22.1 | - | -2.60 |
| 2025-07-31 | VSTM | 6.17 | -22.1 | - | -2.60 |
| 2025-08-01 | VSTM | 6.08 | -22.1 | - | -2.60 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | VSTM | -1.70 | 16.16 | 24.91 |
| 2025-07-07 | VSTM | -1.70 | 16.16 | 24.91 |
| 2025-07-08 | VSTM | -1.70 | 16.16 | 24.91 |
| 2025-07-09 | VSTM | -1.70 | 16.16 | 24.91 |
| 2025-07-10 | VSTM | -1.70 | 16.16 | 24.91 |
| 2025-07-11 | VSTM | -1.70 | 16.16 | 32.21 |
| 2025-07-14 | VSTM | -1.70 | 16.25 | 32.21 |
| 2025-07-15 | VSTM | -1.56 | 16.25 | 32.21 |
| 2025-07-16 | VSTM | -1.56 | 16.25 | 32.21 |
| 2025-07-17 | VSTM | -1.56 | 16.25 | 32.21 |
| 2025-07-18 | VSTM | -1.56 | 16.25 | 32.21 |
| 2025-07-21 | VSTM | -1.56 | 16.27 | 32.21 |
| 2025-07-22 | VSTM | -1.56 | 16.27 | 32.21 |
| 2025-07-23 | VSTM | -1.56 | 16.27 | 32.21 |
| 2025-07-24 | VSTM | -1.56 | 16.27 | 32.21 |
| 2025-07-25 | VSTM | -1.56 | 16.27 | 37.03 |
| 2025-07-28 | VSTM | -1.56 | 16.16 | 37.03 |
| 2025-07-29 | VSTM | -1.56 | 16.16 | 37.03 |
| 2025-07-30 | VSTM | -1.56 | 16.16 | 37.03 |
| 2025-07-31 | VSTM | -1.56 | 16.16 | 37.03 |
| 2025-08-01 | VSTM | -1.56 | 16.16 | 37.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.96
Avg. EPS Est. Current Quarter
-0.74
Avg. EPS Est. Next Quarter
-0.76
Insider Transactions
-1.56
Institutional Transactions
16.16
Beta
0.83
Average Sales Estimate Current Quarter
6
Average Sales Estimate Next Quarter
4
Fair Value
Quality Score
5
Growth Score
38
Sentiment Score
84
Actual DrawDown %
89.7
Max Drawdown 5-Year %
-96.2
Target Price
15.25
P/E
Forward P/E
PEG
P/S
33.41
P/B
P/Free Cash Flow
EPS
-3.19
Average EPS Est. Cur. Y
-2.6
EPS Next Y. (Est.)
-2.77
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1488.76
Relative Volume
0.84
Return on Equity vs Sector %
435.3
Return on Equity vs Industry %
453.9
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading